Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Active targeting of mesoporous silica drug carriers enhances γ-secretase inhibitor efficacy in an in vivo model for breast cancer.

Wittig R, Rosenholm JM, von Haartman E, Hemming J, Genze F, Bergman L, Simmet T, Lindén M, Sahlgren C.

Nanomedicine (Lond). 2014 May;9(7):971-87. doi: 10.2217/nnm.13.62. Epub 2013 Jul 30.

PMID:
23898823
2.

Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer.

Mamaeva V, Rosenholm JM, Bate-Eya LT, Bergman L, Peuhu E, Duchanoy A, Fortelius LE, Landor S, Toivola DM, Lindén M, Sahlgren C.

Mol Ther. 2011 Aug;19(8):1538-46. doi: 10.1038/mt.2011.105. Epub 2011 May 31.

3.

Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy.

Ma'mani L, Nikzad S, Kheiri-Manjili H, Al-Musawi S, Saeedi M, Askarlou S, Foroumadi A, Shafiee A.

Eur J Med Chem. 2014 Aug 18;83:646-54. doi: 10.1016/j.ejmech.2014.06.069. Epub 2014 Jun 28.

PMID:
25014638
4.

Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin S, Wang X, Zhao Y, Ji Z, Zink JI, Nel AE.

ACS Nano. 2013 Feb 26;7(2):994-1005. doi: 10.1021/nn3044066. Epub 2013 Jan 4.

5.

Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.

Ma X, Zhao Y, Ng KW, Zhao Y.

Chemistry. 2013 Nov 11;19(46):15593-603. doi: 10.1002/chem.201302736. Epub 2013 Oct 2.

PMID:
24123533
6.

Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.

Tarn D, Ashley CE, Xue M, Carnes EC, Zink JI, Brinker CJ.

Acc Chem Res. 2013 Mar 19;46(3):792-801. doi: 10.1021/ar3000986. Epub 2013 Feb 6.

7.

Targeted delivery of doxorubicin to mitochondria using mesoporous silica nanoparticle nanocarriers.

Qu Q, Ma X, Zhao Y.

Nanoscale. 2015 Oct 28;7(40):16677-86. doi: 10.1039/c5nr05139h. Epub 2015 Sep 24.

PMID:
26400067
8.

Enhancing Cellular Uptake and Doxorubicin Delivery of Mesoporous Silica Nanoparticles via Surface Functionalization: Effects of Serum.

Shahabi S, Döscher S, Bollhorst T, Treccani L, Maas M, Dringen R, Rezwan K.

ACS Appl Mater Interfaces. 2015 Dec 9;7(48):26880-91. doi: 10.1021/acsami.5b09483. Epub 2015 Nov 20.

PMID:
26562468
9.

Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.

Hanafi-Bojd MY, Jaafari MR, Ramezanian N, Xue M, Amin M, Shahtahmassebi N, Malaekeh-Nikouei B.

Eur J Pharm Biopharm. 2015 Jan;89:248-58. doi: 10.1016/j.ejpb.2014.12.009. Epub 2014 Dec 13.

PMID:
25511563
10.

The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.

Wang D, Huang J, Wang X, Yu Y, Zhang H, Chen Y, Liu J, Sun Z, Zou H, Sun D, Zhou G, Zhang G, Lu Y, Zhong Y.

Biomaterials. 2013 Oct;34(31):7662-73. doi: 10.1016/j.biomaterials.2013.06.042. Epub 2013 Jul 13.

PMID:
23859657
11.

Mesoporous-Silica-Functionalized Nanoparticles for Drug Delivery.

Giret S, Wong Chi Man M, Carcel C.

Chemistry. 2015 Sep 28;21(40):13850-65. doi: 10.1002/chem.201500578. Epub 2015 Aug 6.

PMID:
26250991
12.

Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs.

Xia T, Kovochich M, Liong M, Meng H, Kabehie S, George S, Zink JI, Nel AE.

ACS Nano. 2009 Oct 27;3(10):3273-86. doi: 10.1021/nn900918w.

13.

Tumor-Homing Cell-Penetrating Peptide Linked to Colloidal Mesoporous Silica Encapsulated (-)-Epigallocatechin-3-gallate as Drug Delivery System for Breast Cancer Therapy in Vivo.

Ding J, Yao J, Xue J, Li R, Bao B, Jiang L, Zhu JJ, He Z.

ACS Appl Mater Interfaces. 2015 Aug 19;7(32):18145-55. doi: 10.1021/acsami.5b05618. Epub 2015 Aug 6.

PMID:
26225796
14.

Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage.

Rosenholm JM, Mamaeva V, Sahlgren C, Lindén M.

Nanomedicine (Lond). 2012 Jan;7(1):111-20. doi: 10.2217/nnm.11.166. Review.

PMID:
22191780
15.

Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery.

Baeza A, Colilla M, Vallet-Regí M.

Expert Opin Drug Deliv. 2015 Feb;12(2):319-37. doi: 10.1517/17425247.2014.953051. Epub 2014 Nov 25. Review.

PMID:
25421898
16.

Mesoporous silica nanoparticle-based substrates for cell directed delivery of Notch signalling modulators to control myoblast differentiation.

Böcking D, Wiltschka O, Niinimäki J, Shokry H, Brenner R, Lindén M, Sahlgren C.

Nanoscale. 2014;6(3):1490-8. doi: 10.1039/c3nr04022d.

PMID:
24316607
17.

The intracellular controlled release from bioresponsive mesoporous silica with folate as both targeting and capping agent.

Guo R, Li LL, Zhao WH, Chen YX, Wang XZ, Fang CJ, Feng W, Zhang TL, Ma X, Lu M, Peng SQ, Yan CH.

Nanoscale. 2012 Jun 7;4(11):3577-83. doi: 10.1039/c2nr30425b. Epub 2012 Apr 30.

PMID:
22543578
18.

Mesoporous silica nanoparticles as a compound delivery system in zebrafish embryos.

Sharif F, Porta F, Meijer AH, Kros A, Richardson MK.

Int J Nanomedicine. 2012;7:1875-90. doi: 10.2147/IJN.S26547. Epub 2012 Apr 11.

19.

PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.

Morelli C, Maris P, Sisci D, Perrotta E, Brunelli E, Perrotta I, Panno ML, Tagarelli A, Versace C, Casula MF, Testa F, Andò S, Nagy JB, Pasqua L.

Nanoscale. 2011 Aug;3(8):3198-207. doi: 10.1039/c1nr10253b. Epub 2011 Jul 4.

PMID:
21725561
20.

Functionalized mesoporous silica materials for controlled drug delivery.

Yang P, Gai S, Lin J.

Chem Soc Rev. 2012 May 7;41(9):3679-98. doi: 10.1039/c2cs15308d. Epub 2012 Mar 22. Review.

PMID:
22441299

Supplemental Content

Support Center